Research Shows Improved Cardiovascular Risk Testing Can Yield $187 Million in Health Plan Cost Savings over Five Years
April 23, 2015
Implementing multiple inflammatory biomarker tests to identify cardiovascular disease (CVD) risk can reduce the number of heart attacks and strokes in a health care population and yield substantial cost savings, according to a recent study by a team of researchers from Analysis Group, Cleveland HeartLab (CHL), and MDVIP Inc. As part of the study, "The Economic Impact of Implementing a Multiple Inflammatory Biomarker-Based Approach to Identify, Treat, and Reduce Cardiovascular Risk" (Journal of Medical Economics, April 2015), an Analysis Group team including Principal Howard Birnbaum and Vice President Mihran Yenikomshian developed an economic model to estimate the number of non-fatal myocardial infarction and ischemic stroke events, and their related costs, that would occur in a 1-million-member health care population as a result of implementing multiple inflammatory biomarker tests. Using data from CHL, MDVIP, pharmacy claims data, and literature review, the study suggests that these tests could reduce the number of cardiovascular events by 10 percent over five years, saving more than $187 million in health care costs for a health plan of this size.
"This study shows that by more accurately measuring CVD risk with tools that detect arterial inflammation, we can decrease the overall number of heart attacks and strokes, allowing clinicians and health plans to deploy resources more strategically in order to better manage patient outcomes and costs," said Marc Penn, CHL Chief Medical Officer, in a related CHL press release.